Tiziana Life Sciences Plc. (Nasdaq: TLSA), a biotechnology company developing innovative immunomodulation therapies through cutting-edge drug delivery methods, has today announced that its Chairman and Acting Chief Executive Officer, Gabriele Cerrone, has purchased a further 25,000 of its common shares at $0.58 per share, bringing his total holding to 38,640,737 common shares. This demonstrates the faith that he has in the company’s promising future and its ability to continue to make significant strides in the advancement of its treatments.
Foralumab, the only fully human anti-CD3 monoclonal antibody (mAb), is capable of calming inflammation and modulating T cell function. This effect has been observed in patients with COVID, multiple sclerosis and healthy normal subjects. With the potential to revolutionize the treatment of inflammatory human diseases, intranasal foralumab Phase 2 trials are set to begin in Q3 2023 in patients with non-active SPMS. Activated T cells play a crucial role in the inflammatory process and the hope is that foralumab will help to reduce the symptoms associated with these diseases.
About Tiziana Life Sciences
Tiziana Life Sciences is revolutionizing the world of immunotherapy with its transformational drug delivery technologies. By leveraging alternative routes of administration, such as nasal, oral, and inhalation, their therapies offer the potential for greater efficacy, safety, and tolerability than traditional intravenous (IV) delivery.
Their lead candidate, intranasal foralumab, is the first fully human anti-CD3 mAb, and has already shown promising results in clinical trials. Tiziana’s technologies are also protected by several patents and pending applications, opening the door to a pipeline of potential applications.